Delivered-To: oc.tjphuhs@gmail.com Received: by 2002:a05:6400:300a:b0:2d0:8b88:944 with SMTP id 10csp793031ecq; Sat, 2 May 2026 13:58:34 -0700 (PDT) X-Received: by 2002:a05:6102:598e:b0:610:92a1:15c5 with SMTP id ada2fe7eead31-62d87c82f6dmr1994423137.31.1777755514146; Sat, 02 May 2026 13:58:34 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1777755514; cv=none; d=google.com; s=arc-20240605; b=k2c2JCzexq9CmtKC5hQe2Io1Sq5Er3FIzQol9YQmOV7PicblQ/MPtFwaUCwAljw8sC oXxgAWEN+VhY2mn3VAXTYq8tfjAy5m1MSG1Blr+xzMN2k7923Si4/5kAVYuC1qV1S81a rh3ZaFEg25q1GC4o2/U3o0cHwPJEUI/LCKv9OCftbyfolnsNixj9P+HmGELpzH/olgsL LxinBcVqMYw5qk0wC4FtkQ2bEoIMJzws44sdmrsbYxdUMuhNjTr5Kc2WF1G1iJliTVTM VgwSpb8sLmVryMaqEXukH7HraXhH3zMk+L+gvbEH1twwerXS4D3sgPLvyDupsS7qkl76 pMOg== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :dkim-signature; bh=haHhrtyzpg/uNCj0iqiDzYg137VaH9vtU4H/zbBoadQ=; fh=F6Qtq/PC/9aW+A0Z/30DYnuZeFJIQSXKTJRrYsjMofs=; b=IrpR0cIeYQT8dwkiCVuCWSPqI0zsIltBRLps5Ymal00fevo47zH1VxGIr6jgDl+mHf G/wk+Q2XO13rT4aw3Dr4g7v8IEkJfE8VfRoOPUg89uq5slKlI1CDb9ZTdLXr9nmp5ip3 LKHNCIGUd9ayDv0NAQpBDzP1qypVqHrkUHa0o5qGZKEo+tYda1is8ipIL4z+EI/+rysO BYhxWCQgpVxcGQxAaR++aYphaPI1o37GRDuE3NOJxunBPk+Q01TKLl0R1mUyheEVz6dz UuO1a52c8xD9gQiiNkhWhhAj9hdyCyy3SXNy1UUXEScf2AIE57+cl7IxaEpUTcIBpK90 tqPg==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@gmail.com header.s=20251104 header.b=OzRBXaKS; spf=pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) smtp.mailfrom=tjphuhs@gmail.com; dmarc=pass (p=NONE sp=QUARANTINE dis=NONE) header.from=gmail.com; dara=pass header.i=@gmail.com Return-Path: Received: from mail-sor-f41.google.com (mail-sor-f41.google.com. [209.85.220.41]) by mx.google.com with SMTPS id a1e0cc1a2514c-95ce8c26302sor1023851241.10.2026.05.02.13.58.33 for (Google Transport Security); Sat, 02 May 2026 13:58:34 -0700 (PDT) Received-SPF: pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) client-ip=209.85.220.41; Authentication-Results: mx.google.com; dkim=pass header.i=@gmail.com header.s=20251104 header.b=OzRBXaKS; spf=pass (google.com: domain of tjphuhs@gmail.com designates 209.85.220.41 as permitted sender) smtp.mailfrom=tjphuhs@gmail.com; dmarc=pass (p=NONE sp=QUARANTINE dis=NONE) header.from=gmail.com; dara=pass header.i=@gmail.com DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=gmail.com; s=20251104; t=1777755511; x=1778360311; dara=google.com; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :from:to:cc:subject:date:message-id:reply-to; bh=haHhrtyzpg/uNCj0iqiDzYg137VaH9vtU4H/zbBoadQ=; b=OzRBXaKSGJrOnc2/K2UTmv53k19a0yeHhmvg/h3JzxfkcU9PjkW2xCDxDPkov0FxxW u3vYAjSwTy4551oTvidN63e/pfNF8wUy/jTAN2Fbh4+x7uaV+zkLSA2nMowYyMi6ofBu QbNEGh6GPIrxIYUfapbRSDlPUvyjycTXcYalpJpG4iOoxj2YjVa5kOGP/Z6/NTOnss4n Os8xx5RXV+ulxbcXkp6tyndne2E49MgaRjFwqbq6SnzhJRm3yq0YEFHNSENYPLM7uRH9 A97F/rssBwrltx8PXQnbf1S1iec3jlxaQJsITTwnp/4gIEFinJu4sEGsFxcKEXiM3Wb6 2+0w== X-Google-DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed; d=1e100.net; s=20251104; t=1777755511; x=1778360311; h=mime-version:subject:references:in-reply-to:message-id:to:from:date :x-gm-gg:x-gm-message-state:from:to:cc:subject:date:message-id :reply-to; bh=haHhrtyzpg/uNCj0iqiDzYg137VaH9vtU4H/zbBoadQ=; b=mrrKCBe2hkuse4fg05reVl9nQwsUYpOIUQcaX+sqXuCb5E9b+QeMQoysr9sy0xCBQy 7ZhuLxeQbAobwlFT/Od/gCHmSyfhmYwR2BGMFMYSyn8RUMXe9J4yXREkM0aioy8uiIfH fNoLPE+T0aPUr24YO3sID95at4lONiSce25zD9+FaperoEzZFWVAOMV/ITpjsD/HP5YO U3ngvSeObnc6iQriVMIDadKTOoE/rHxfQDCs67bPMisRxE1YcpsIPvQwzgm7u59eeBXr 1d+v25XIt9V3zw8tIgXe610gsSM+eoMFnDb+3yXs+6n8kNGJTFQ9FNXIBZld2BwqoM0m ECjw== X-Gm-Message-State: AOJu0Yz9nVgqHdiT4mKm7h8ob9ZeoEwSq92SMw7uumv4rRm9Vby/ohgP yf7Xj8KGGWdrR4cn8Gf52AknN7vwVun/0t8/kdhOtHCP5GzqRVEfev2DeXmBpfJH X-Gm-Gg: AeBDievh9YMvHk7mZ0aJElQqnoHPLJxxhVsuo5qbvcfqE6IiSzXddxHBRmRHEbbolpf T+azOviUA0QybvQIfcUNyy4zpqRibFvxkxP9GKxNvlmVTGjGXzKJHvBxvO4aDq7x6kUIK9nQTMJ StQAaLqqqiZWd/w4YttcaBaMKfctIVXdZiRPQ7mUM33j/bBEUKf1gCKyMgqngQmCov1pxBfrQ7q nMAIBQmNQ4uCTcmZbtBfC1DjUsf/bXJK2BzQr3JivyMmBhPhdRhUcddsW85wyjlEHVohVEla+rl SDE+gO5Eyn20MpxMXGFOBpsG4paMBpRTftgijclbg613S6bb9X+CBsX9DigSjLsJyfiFlcLp9VR nSzRLw3mV/RLsF0PGEPJ5Zv/wZsRLCIWI6rK/9O0TuHEwFnTrnO2k9cuxzdhSGyg3LdnzyHd6ym Vbd16ULoVX/4krGL/7fjmVRRxIA4m/dUR7iwZKcT4aGuIeOg== X-Received: by 2002:a05:6122:1d0b:b0:56e:f262:9109 with SMTP id 71dfb90a1353d-5750c4623c9mr2174418e0c.2.1777755510908; Sat, 02 May 2026 13:58:30 -0700 (PDT) Return-Path: Received: from [192.168.1.81] ([97.106.1.95]) by smtp.gmail.com with ESMTPSA id 71dfb90a1353d-574a6dc7dd4sm3776672e0c.14.2026.05.02.13.58.27 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Sat, 02 May 2026 13:58:29 -0700 (PDT) Date: Sat, 2 May 2026 16:58:06 -0400 From: tjphuhs@gmail.com To: "=?utf-8?Q?oc.tjphuhs=40gmail.com?=" Message-ID: <25b17fc6-7249-49d9-8e5a-b78ad9a49c30@Spark> In-Reply-To: <20260502151656.3.644bc004829c322a@mg2.substack.com> References: <20260502151656.3.644bc004829c322a@mg2.substack.com> Subject: Fwd: Urolithin A: The Most Underrated Compound in Longevity X-Readdle-Message-ID: 25b17fc6-7249-49d9-8e5a-b78ad9a49c30@Spark MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="69f66573_3c00c9e0_cf0f" --69f66573_3c00c9e0_cf0f Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline ---------- =46orwarded message ---------- =46rom: Derek from Research Radar Date: May 2, 2026 at 11:17=E2=80=AFAM -0400 To: tjphuhs=40gmail.com Subject: Urolithin A: The Most Underrated Compound in Longevity > A postbiotic that targets the upstream cause of aging =E2=80=94 and why= almost nobody in the peptide world is talking about it > =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0= =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2= =AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2= =A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87= =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F= =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80= =87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD= =8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2= =80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD= =CD=8F =C2=A0 =E2=80=87 =C2=AD=CD=8F =C2=A0 =E2=80=87 =C2=AD > =46orwarded this email=3F Subscribe here for more > Urolithin A: The Most Underrated Compound in Longevity > A postbiotic that targets the upstream cause of aging =E2=80=94 and why= almost nobody in the peptide world is talking about it > Derek > May 2 > > READ IN APP > > Research and educational purposes only. Nothing in this piece is medica= l advice. If you=E2=80=99re considering anything personally, that=E2=80=99= s a conversation for a qualified clinician. > I want to talk about something that isn=E2=80=99t a peptide but probabl= y deserves a permanent spot in the longevity conversation alongside them:= Urolithin A. > Upgrade to paid > If you=E2=80=99ve been around the research community long enough, you=E2= =80=99ve heard of NAD+, rapamycin, metformin, GLP-1s, GHK-Cu, MOTS-c, SS-= 31. All of them have legitimate mechanisms. Urolithin A =E2=80=94 UA from= here on =E2=80=94 quietly checks more boxes than almost anything I=E2=80= =99ve come across, and I rarely see it discussed at the depth it deserves= . > This piece walks through what it is, how it works, the mechanisms relev= ant to aging and neurodegeneration, what the human data actually shows, a= nd how researchers are thinking about it. Beginner-friendly, but with eno= ugh depth to be genuinely useful. > What Urolithin A Actually Is > UA is a postbiotic =E2=80=94 a compound your gut bacteria produce when = they metabolize certain dietary precursors called ellagitannins and ellag= ic acid. Those precursors are found in pomegranates (the highest source),= walnuts, strawberries, raspberries, blackberries, and almonds. > Sounds simple. Eat the foods, get the compound. Here=E2=80=99s the catc= h: > > Roughly 60% of people lack the specific gut bacteria needed to conver= t ellagitannins into UA. Even among the =7E40% who can produce it, the am= ounts vary wildly based on microbiome composition, diet, age, and antibio= tic history. > This is why direct UA supplementation became a research area to begin w= ith. It bypasses the microbiome lottery. > UA was first identified as a mitophagy inducer in a 2016 Nature Medicin= e paper from researchers at Amazentis and EP=46L, where it extended lifes= pan in C. elegans and improved muscle function in rodents. Since then the= research has exploded. > The Master Mechanism: Mitophagy > To understand why UA matters, you have to understand mitophagy. > Mitochondria are the energy producers inside every cell. They make ATP,= regulate cell death, handle calcium, and produce reactive oxygen species= . They=E2=80=99re also one of the first things to break down with age. > Here=E2=80=99s the problem: as you age, your cells stop efficiently cle= aring out damaged mitochondria. Dysfunctional mitochondria pile up, leak = oxidative stress, fail to make energy efficiently, and contribute to near= ly every =E2=80=9Challmark of aging=E2=80=9D you can name. > Mitophagy is the cellular cleanup process that selectively removes dama= ged mitochondria so new, healthy ones can take their place. It=E2=80=99s = one of the most important quality-control systems in the body. > UA is one of the only known compounds that directly and reliably induce= s mitophagy in humans at oral doses. That alone would be remarkable. But = the downstream effects of restoring mitophagy ripple through nearly every= aging-related system. > Mechanisms Relevant to Aging > Let=E2=80=99s break down what researchers have actually documented. > Mitochondrial quality control. UA activates the PINK1/Parkin pathway =E2= =80=94 the primary signaling cascade that tags damaged mitochondria for r= emoval. In human muscle biopsies from clinical trials, UA supplementation= increased expression of mitophagy genes including PINK1, Parkin, ATG7, a= nd LC3B. This isn=E2=80=99t theoretical. It=E2=80=99s been measured in hu= man tissue. > Mitochondrial biogenesis. After clearing damaged mitochondria, you need= new ones. UA upregulates pathways involved in making fresh mitochondria,= including AMPK signaling and Nrf2 activation. Research published in 2025= also identified the SKN-1/Nrf2 and CAMK2D pathways as essential for UA=E2= =80=99s lifespan-extending effects. > Calcium signaling and inter-organellar communication. Newer 2025 resear= ch from the Palikaras lab showed UA modulates calcium signaling between t= he ER, mitochondria, and lysosomes =E2=80=94 restoring =E2=80=9Ccrosstalk= =E2=80=9D between these organelles that breaks down with age. Calcium che= lation completely abolished UA=E2=80=99s benefits, which tells us calcium= signaling is central to how it works. > Reduced cellular senescence. Senescent cells =E2=80=94 the so-called =E2= =80=9Czombie cells=E2=80=9D =E2=80=94 are dysfunctional cells that don=E2= =80=99t die when they should and pump out inflammatory signals. UA mitiga= tes stress-induced senescence in mammalian cells in a calcium-dependent m= anner. > Anti-inflammatory effects. UA reduces systemic inflammation. Human tria= ls have shown reductions in C-reactive protein (CRP) =E2=80=94 a major in= flammation biomarker. It modulates N=46-=CE=BAB signaling and reduces pro= -inflammatory cytokines. > Improved mitochondrial efficiency. Plasma acylcarnitines =E2=80=94 mark= ers of inefficient fatty acid oxidation =E2=80=94 decrease with UA supple= mentation in humans, indicating mitochondria are processing fuel more eff= iciently. > AhR/Nrf2 antioxidant activation. UA activates the aryl hydrocarbon rece= ptor and Nrf2 pathways, which collectively drive expression of antioxidan= t defense genes and reduce oxidative stress. > Mechanisms Relevant to Neurodegeneration > This is the section that doesn=E2=80=99t get enough attention. UA cross= es the blood-brain barrier, and the preclinical neuroprotective data is g= enuinely impressive across multiple disease models. > Alzheimer=E2=80=99s disease (preclinical) > In multiple AD mouse models =E2=80=94 APP/PS1, 3xTgAD, and DNA-repair-d= eficient ADP mice =E2=80=94 UA treatment has been shown to: > > =E2=80=A2 > Reduce amyloid-beta plaque accumulation > =E2=80=A2 > Decrease tau hyperphosphorylation > =E2=80=A2 > Improve cognition on standard memory tests > =E2=80=A2 > Restore mitophagy and lysosomal function in neurons > =E2=80=A2 > Inhibit DYRK1A, a kinase implicated in tau pathology and Do= wn syndrome=E2=80=93associated AD > =E2=80=A2 > Reduce neuroinflammation > > The proposed mechanism: AD brains accumulate damaged mitochondria and f= ail to clear them. UA restores that cleanup, and the downstream effect ap= pears to be protection of neurons from amyloid and tau toxicity. > Parkinson=E2=80=99s disease (preclinical) > In MPTP-induced PD models and A53T =CE=B1-synuclein transgenic mice, UA= has demonstrated: > > =E2=80=A2 > Protection of dopaminergic neurons from MPTP-induced damage= > =E2=80=A2 > Reduction of motor deficits > =E2=80=A2 > Reversal of cognitive impairment, a major non-motor PD symp= tom > =E2=80=A2 > Decreased hippocampal neuroinflammation > =E2=80=A2 > Reduced dendritic spine loss and synaptic damage > =E2=80=A2 > Activation of the AKT/CREB/BDN=46 signaling pathway, critic= al for neuroplasticity and synaptic health > > The PD research is particularly interesting because dopaminergic neuron= s are extraordinarily mitochondria-dependent, and mitochondrial dysfuncti= on is widely implicated as a driver of PD pathology. > Stroke and multiple sclerosis > Preclinical models of ischemic stroke and MS have shown neuroprotective= effects of UA, primarily through anti-inflammatory and mitochondrial pro= tection mechanisms. > The important caveat > Almost all neurodegeneration data is preclinical =E2=80=94 cell and ani= mal models. Human clinical trials in AD or PD specifically haven=E2=80=99= t been completed yet. The Alzheimer=E2=80=99s Drug Discovery =46oundation= has noted that for neurodegeneration, UA may need to be started early =E2= =80=94 well before clinical disease onset =E2=80=94 to provide meaningful= protection. > This is consistent with a broader theme that runs through the whole lon= gevity field: > > Mitophagy interventions probably work better as long-term resilience = tools than as late-stage rescue therapies. > What the Human Data Actually Shows > This is where UA separates itself from a lot of =E2=80=9Cpromising=E2=80= =9D compounds. We have actual placebo-controlled human trials. > Phase 1 safety trial (Ryu et al., 2019). Tested in healthy elderly adul= ts at 250=E2=80=932000 mg single doses and 250/500/1000 mg/day for 28 day= s. =46avorable safety profile at all doses. Bioavailable in plasma at all= doses. Modulated mitochondrial gene expression in muscle biopsies at 500= and 1000 mg. > Phase 2 in middle-aged adults (Singh et al., 2022, Cell Reports Medicin= e =E2=80=94 the ATLAS trial). 88 sedentary middle-aged adults, 4 months o= f supplementation, 500 mg or 1000 mg daily. Results: roughly 12% improvem= ent in leg muscle strength, clinically meaningful improvements in VO2 pea= k and 6-minute walk test at 1000 mg, reduced plasma acylcarnitines (bette= r mitochondrial fuel efficiency), reduced CRP (lower inflammation), and i= ncreased mitophagy and mitochondrial proteins in muscle biopsies. > 2025 cardiovascular trial (iScience). UA improved cardiovascular biomar= kers in humans. Preclinical models showed reversal of systolic and diasto= lic dysfunction in aging hearts and heart failure models. > 2025 immune function trial (Nature Aging). 50 healthy adults, 1000 mg/d= ay for 4 weeks. Improved markers of immune fitness. > Dosing patterns from the literature > 500 mg/day shows benefit but consistently less than 1000 mg. 1000 mg/da= y is the dose used in most positive trials and appears to be the evidence= -supported dose. Timing: morning, with or without food =E2=80=94 absorpti= on isn=E2=80=99t significantly affected by food. Time to effect: gene exp= ression changes appear within 4 weeks; functional improvements typically = reported at 2=E2=80=934 months. > Why I Think UA Is Underrated > Here=E2=80=99s my honest take after digging through this. > It targets mitophagy directly. Almost no other oral compound does this = reliably in humans. Mitophagy decline is one of the most fundamental driv= ers of aging. > It=E2=80=99s a postbiotic, not a synthetic drug. Your gut already makes= it, sometimes. The body already has machinery to handle it. The safety p= rofile across trials reflects this. > The mechanisms are convergent. Mitochondrial quality, inflammation, sen= escence, neuroprotection, muscle function, cardiovascular function, immun= e function =E2=80=94 these aren=E2=80=99t separate problems. They=E2=80=99= re all downstream of mitochondrial decline. A compound that addresses the= upstream cause has multi-system effects. > The human data is real. This isn=E2=80=99t a =E2=80=9Crodents only=E2=80= =9D story. We have multiple placebo-controlled human trials with measured= outcomes in muscle biopsies, plasma biomarkers, and functional performan= ce. > It pairs logically with other interventions. It doesn=E2=80=99t compete= with peptides, exercise, or other longevity tools. It addresses a differ= ent layer of the cellular machinery. > What I think holds it back from broader awareness: it=E2=80=99s not fla= shy or new, no instant subjective effect like a stimulant or peptide cycl= e. Effects are slow and structural, measured in weeks to months. Marketin= g has been dominated by one premium-priced commercial brand, which has sh= aped the conversation. And it doesn=E2=80=99t fit cleanly into the peptid= e narrative, so peptide-focused communities (mine included) sometimes ove= rlook it. > A Note on Product Quality > One thing worth flagging if you=E2=80=99re researching this further: th= e supplement market for UA is a mess. > A lot of products labeled =E2=80=9CUrolithin A=E2=80=9D or =E2=80=9Cpom= egranate complex=E2=80=9D actually contain ellagitannin or ellagic acid b= lends =E2=80=94 the precursors, not UA itself. Remember, =7E60% of people= can=E2=80=99t efficiently convert those precursors. So buying a =E2=80=9C= pomegranate extract=E2=80=9D hoping to get UA is essentially gambling on = your microbiome. > When you check labels, you want to see Urolithin A listed directly as t= he active ingredient, with a specified milligram amount =E2=80=94 not a =E2= =80=9Cproprietary blend=E2=80=9D hiding the dose, and not just =E2=80=9Ce= llagitannins=E2=80=9D or =E2=80=9Cellagic acid.=E2=80=9D > The honest reality: every single published human clinical trial on UA h= as used Mitopure, made by Amazentis and sold under the Timeline brand. It= =E2=80=99s a patented form with greater than 98% purity. That=E2=80=99s n= ot me selling it =E2=80=94 that=E2=80=99s just what the literature shows.= When researchers wanted to study UA in humans, this is the form they use= d. Generic UA products may be perfectly fine, but they don=E2=80=99t have= direct clinical data behind them at specified doses. Some are well-teste= d by third parties; others aren=E2=80=99t. > If you want the version that matches the clinical trial literature exac= tly: Timeline Mitopure on Amazon > If you go with a generic UA product, look for: > > =E2=80=A2 > Urolithin A listed as the active ingredient (not =E2=80=9Cp= omegranate extract=E2=80=9D or =E2=80=9Cellagitannin complex=E2=80=9D) > =E2=80=A2 > A specified mg dose, 500 mg or 1000 mg per serving to match= the trial doses > =E2=80=A2 > Third-party testing or COA available > =E2=80=A2 > A reputable brand with transparent sourcing > > Either way =E2=80=94 verify the label says Urolithin A, not a precursor= complex. > Things Worth Researching =46urther > If you=E2=80=99re going down the rabbit hole, here=E2=80=99s what=E2=80= =99s worth understanding more deeply. > Mitophagy biology in general =E2=80=94 PINK1/Parkin, BNIP3, NIX pathway= s. The hallmarks of aging (L=C3=B3pez-Ot=C3=ADn et al.) and where mitocho= ndrial dysfunction sits among them. Microbiome variability =E2=80=94 why = some people convert ellagitannins to UA and others don=E2=80=99t. Synergy= with NAD+ precursors, exercise, and caloric restriction, all of which af= fect mitochondrial pathways. The 2025 Palikaras lab paper on calcium-depe= ndent mitophagy and inter-organellar communication =E2=80=94 the most mec= hanistically sophisticated UA paper I=E2=80=99ve seen. And the question o= f long-term effects: most trials are 4 weeks to 4 months. Lifespan-style = data in humans doesn=E2=80=99t exist yet. > =46inal Thoughts > UA is one of those compounds that doesn=E2=80=99t get talked about enou= gh because it doesn=E2=80=99t have a sexy story. There=E2=80=99s no =E2=80= =9Cyou=E2=80=99ll feel it on day one.=E2=80=9D There=E2=80=99s no dramati= c transformation photo. What there is, is a steadily growing body of evid= ence that it does something genuinely fundamental at the cellular level =E2= =80=94 restoring a process that nearly every other longevity intervention= is trying to influence indirectly. > If aging is partly a story about damaged mitochondria piling up faster = than your cells can clear them, UA is one of the few tools that addresses= that exact problem head-on. > Whether that translates into long-term human longevity outcomes is a qu= estion the next decade of research will answer. But the mechanisms, the h= uman safety data, and the multi-system effects already make it worth know= ing about deeply =E2=80=94 even if you never personally use it. > This is for research and educational purposes only. Nothing in this pie= ce is medical advice, and this isn=E2=80=99t a recommendation to use UA p= ersonally. If you=E2=80=99re interested in the topic for any non-research= reason, that=E2=80=99s a conversation for a qualified medical profession= al who knows your situation. > If this was useful, share it with someone who=E2=80=99s been chasing th= e longevity rabbit hole and hasn=E2=80=99t come across UA yet =E2=80=94 a= nd let me know in the comments what underrated compound you=E2=80=99d lik= e me to break down next. > =E2=80=94 Derek > References > =46oundational mitophagy research > Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy a= nd prolongs lifespan in C. elegans and increases muscle function in roden= ts. Nature Medicine. 2016;22(8):879-888. doi:10.1038/nm.4132 > Phase 1 human safety and bioavailability > Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolit= hin A is safe and induces a molecular signature of improved mitochondrial= and cellular health in humans. Nature Metabolism. 2019;1(6):595-603. =46= ull text > Phase 2 muscle strength and exercise performance trial (ATLAS) > Singh A, D=E2=80=99Amico D, Andreux PA, et al. Urolithin A improves mus= cle strength, exercise performance, and biomarkers of mitochondrial healt= h in a randomized trial in middle-aged adults. Cell Reports Medicine. 202= 2;3(5):100633. =46ull text > 2025 cardiovascular trial > Liu S, =46aitg J, Tissot C, et al. Urolithin A provides cardioprotectio= n and mitochondrial quality enhancement preclinically and improves human = cardiovascular health biomarkers. iScience. 2025;28(2):111814. =46ull tex= t > 2025 calcium-dependent mitophagy and inter-organellar mechanism > Roussos A, Kitopoulou K, Borbolis =46, et al. Urolithin A modulates int= er-organellar communication via calcium-dependent mitophagy to promote he= althy ageing. Autophagy. 2025;21(12):3097-3122. =46ull text > Muscle aging mechanism review > =46aitg J, D=E2=80=99Amico D, Rinsch C, Singh A. Mitophagy Activation b= y Urolithin A to Target Muscle Aging. Calcified Tissue International. 202= 4;114(1):53-59. =46ull text > Sports nutrition applications > Emerging evidence of Urolithin A in sports nutrition: bridging preclini= cal findings to athletic applications. =46rontiers in Nutrition. 2025;12:= 1585922. =46ull text > Alzheimer=E2=80=99s disease (preclinical) > Jayatunga DPW, Hone E, Khaira H, et al. Therapeutic Potential of Mitoph= agy-Inducing Microflora Metabolite, Urolithin A for Alzheimer=E2=80=99s D= isease. Nutrients. 2021;13(11):3744. =46ull text > Urolithin A improves Alzheimer=E2=80=99s disease cognition and restores= mitophagy and lysosomal functions. bioRxiv. 2024. Preprint > Parkinson=E2=80=99s disease (preclinical) > Urolithin A in Health and Diseases: Prospects for Parkinson=E2=80=99s D= isease Management. Antioxidants. 2023;12(7):1479. =46ull text > Urolithin A improves Parkinson=E2=80=99s disease-associated cognitive i= mpairment through modulation of neuroinflammation and neuroplasticity. Ex= perimental Neurology. 2025. PubMed > Comprehensive CNS review > Urolithin A in Central Nervous System Disorders: Therapeutic Applicatio= ns and Challenges. Biomedicines. 2025;13(7):1553. =46ull text > Heart failure (H=46pE=46) > Urolithin A Restores Mitochondrial =46unction and Reverses Cardiac Remo= deling in Heart =46ailure with Preserved Ejection =46raction. bioRxiv. 20= 25. Preprint > Independent supplement assessment > Alzheimer=E2=80=99s Drug Discovery =46oundation Cognitive Vitality Repo= rt =E2=80=94 Urolithin A > Upgrade to paid > You're currently a free subscriber to Research Radar. =46or the full ex= perience, upgrade your subscription. > Upgrade to paid > > Share > > > Like > Comment > Restack > > =C2=A9 2026 Derek Pruski > 548 Market Street PMB 72296, San =46rancisco, CA 94104 > Unsubscribe --69f66573_3c00c9e0_cf0f Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable Content-Disposition: inline
---------- =46orwarded message ----= ------
=46rom: Derek from Research Radar <derekpruski=40substack.com&g= t;
Date: May 2, 2026 at 11:17=E2=80=AFAM -0400
To: tjphuhs=40gmail.com
Subject: Urolithin A: The Most Underrated Compound in Longevity
3D=22=22
A postbiotic that targets the upstream cause of aging =E2=80=94 = and why almost nobody in the peptide world is talking about it
=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23= 160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80= =87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD= =CD=8F &=23160; =E2=80=87 =C2=AD=CD=8F &=23160; =E2=80=87 =C2=AD
=46orwarded this email=3F Subscribe here for more

Urolithin A: The Most Underrated Compound in Longevity

A postbiotic that targets the upstream caus= e of aging =E2=80=94 and why almost nobody in the peptide world is talkin= g about it

Derek
&=23160;=
3D=22=22=
3D=22=22
3D=22=22
READ IN APP3D=
&=23160;=

Research and educational purposes on= ly. Nothing in this piece is medical advice. If you=E2=80=99re considerin= g anything personally, that=E2=80=99s a conversation for a qualified clin= ician.

I want to talk about something that isn=E2=80=99= t a peptide but probably deserves a permanent spot in the longevity conve= rsation alongside them: Urolithin A.=

3D=22=22
Upgrade t= o paid

If you=E2=80=99ve been around the research community l= ong enough, you=E2=80=99ve heard of NAD+, rapamycin, metformin, GLP-1s, G= HK-Cu, MOTS-c, SS-31. All of them have legitimate mechanisms. Urolithin A= =E2=80=94 UA from here on =E2=80=94 quietly checks more boxes than almos= t anything I=E2=80=99ve come across, and I rarely see it discussed at the= depth it deserves.

This piece walks through what it is, how it works, the= mechanisms relevant to aging and neurodegeneration, what the human data = actually shows, and how researchers are thinking about it. Beginner-frien= dly, but with enough depth to be genuinely useful.

What Urolithin A Actually Is

UA is a postbiotic =E2=80=94 a compound your gut bacteria produce when they metabolize cert= ain dietary precursors called ellagitannins and ellagic acid. Those precursors are found in pomegranat= es (the highest source), walnuts, strawberries, raspberries, blackberries= , and almonds.

Sounds simple. Eat the foods, get the compound. Here=E2= =80=99s the catch:

Roughly 60% of people lack the speci= fic gut bacteria needed to convert ellagitannins into UA. Even among the = =7E40% who can produce it, the amounts vary wildly based on microbiome co= mposition, diet, age, and antibiotic history.

This is why direct UA supplementation became a researc= h area to begin with. It bypasses the microbiome lottery.

UA was first identified as a mitophagy inducer i= n a 2016 Nature Medicine paper from researchers at = Amazentis and EP=46L, where it extended lifespan in C. elegans= and improved muscle function in rodents. Since then the resea= rch has exploded.

The Master Mechanism: Mitophagy<= /h2>

To understand why UA matters, you have to understand m= itophagy.

Mitochondria are the energy producers inside every cel= l. They make ATP, regulate cell death, handle calcium, and produce reacti= ve oxygen species. They=E2=80=99re also one of the first things to break = down with age.

Here=E2=80=99s the problem: as you age, your cells sto= p efficiently clearing out damaged mitochondria. Dysfunctional mitochondr= ia pile up, leak oxidative stress, fail to make energy efficiently, and c= ontribute to nearly every =E2=80=9Challmark of aging=E2=80=9D you can nam= e.

Mitophagy is the cellular clean= up process that selectively removes damaged mitochondria so new, healthy = ones can take their place. It=E2=80=99s one of the most important quality= -control systems in the body.

UA is one of the only known compounds that directly and reliably induces mitophagy in humans at ora= l doses. That alone would be remarkable. But the downstream effects of re= storing mitophagy ripple through nearly every aging-related system.

Mechanisms Relevant to Aging

Let=E2=80=99s break down what researchers have actuall= y documented.

Mitochondrial quality control. = UA activates the PINK1/Parkin pathway =E2=80=94 the primary signaling cas= cade that tags damaged mitochondria for removal. In human muscle biopsies= from clinical trials, UA supplementation increased expression of mitopha= gy genes including PINK1, Parkin, ATG7, and LC3B. This isn=E2=80=99t theo= retical. It=E2=80=99s been measured in human tissue.

Mitochondrial biogenesis. After= clearing damaged mitochondria, you need new ones. UA upregulates pathway= s involved in making fresh mitochondria, including AMPK signaling and Nrf= 2 activation. Research published in 2025 also identified the SKN-1/Nrf2 a= nd CAMK2D pathways as essential for UA=E2=80=99s lifespan-extending effec= ts.

Calcium signaling and inter-organellar communi= cation. Newer 2025 research from the Palikaras lab showed = UA modulates calcium signaling between the ER, mitochondria, and lysosome= s =E2=80=94 restoring =E2=80=9Ccrosstalk=E2=80=9D between these organelle= s that breaks down with age. Calcium chelation completely abolished UA=E2= =80=99s benefits, which tells us calcium signaling is central to how it w= orks.

Reduced cellular senescence. Se= nescent cells =E2=80=94 the so-called =E2=80=9Czombie cells=E2=80=9D =E2=80= =94 are dysfunctional cells that don=E2=80=99t die when they should and p= ump out inflammatory signals. UA mitigates stress-induced senescence in m= ammalian cells in a calcium-dependent manner.

Anti-inflammatory effects. UA r= educes systemic inflammation. Human trials have shown reductions in C-rea= ctive protein (CRP) =E2=80=94 a major inflammation biomarker. It modulate= s N=46-=CE=BAB signaling and reduces pro-inflammatory cytokines.

Improved mitochondrial efficiency. Plasma acylcarnitines =E2=80=94 markers of inefficient fatty acid oxi= dation =E2=80=94 decrease with UA supplementation in humans, indicating m= itochondria are processing fuel more efficiently.

AhR/Nrf2 antioxidant activation. UA activates the aryl hydrocarbon receptor and Nrf2 pathways, which col= lectively drive expression of antioxidant defense genes and reduce oxidat= ive stress.

Mechanisms Relevant to Neurodege= neration

This is the section that doesn=E2=80=99t get enough at= tention. UA crosses the blood-brain barrier, and the preclinical neuropro= tective data is genuinely impressive across multiple disease models.

Alzheimer=E2=80=99s disease (pre= clinical)

In multiple AD mouse models =E2=80=94 APP/PS1, 3xTgAD,= and DNA-repair-deficient ADP mice =E2=80=94 UA treatment has been shown = to:

  • Reduc= e amyloid-beta plaque accumulation

  • Decre= ase tau hyperphosphorylation

  • Impro= ve cognition on standard memory tests

  • Resto= re mitophagy and lysosomal function in neurons

  • Inhib= it DYRK1A, a kinase implicated in tau pathology and Down syndrome=E2=80=93= associated AD

  • Reduc= e neuroinflammation

The proposed mechanism: AD brains accumulate damaged m= itochondria and fail to clear them. UA restores that cleanup, and the dow= nstream effect appears to be protection of neurons from amyloid and tau t= oxicity.

Parkinson=E2=80=99s disease (pre= clinical)

In MPTP-induced PD models and A53T =CE=B1-synuclein tr= ansgenic mice, UA has demonstrated:

  • Prote= ction of dopaminergic neurons from MPTP-induced damage

  • Reduc= tion of motor deficits

  • Rever= sal of cognitive impairment, a major non-motor PD symptom

  • Decre= ased hippocampal neuroinflammation

  • Reduc= ed dendritic spine loss and synaptic damage

  • Activ= ation of the AKT/CREB/BDN=46 signaling pathway, critical for neuroplastic= ity and synaptic health

The PD research is particularly interesting because do= paminergic neurons are extraordinarily mitochondria-dependent, and mitoch= ondrial dysfunction is widely implicated as a driver of PD pathology.

=

Stroke and multiple sclerosis

Preclinical models of ischemic stroke and MS have show= n neuroprotective effects of UA, primarily through anti-inflammatory and = mitochondrial protection mechanisms.

The important caveat

Almost all neurodegeneration data is preclinical= =E2=80=94 cell and animal models. Human clinical trials in AD or PD spec= ifically haven=E2=80=99t been completed yet. The Alzheimer=E2=80=99s Drug= Discovery =46oundation has noted that for neurodegeneration, UA may need= to be started early =E2=80=94 well before clinical= disease onset =E2=80=94 to provide meaningful protection.

This is consistent with a broader theme that runs thro= ugh the whole longevity field:

Mitophagy interventions probably wor= k better as long-term resilience tools than as late-stage rescue therapie= s.

What the Human Data Actually Sho= ws

This is where UA separates itself from a lot of =E2=80= =9Cpromising=E2=80=9D compounds. We have actual placebo-controlled human = trials.

Phase 1 safety trial (Ryu et al., 2019). Tested in healthy elderly adults at 250=E2=80=932000 mg single = doses and 250/500/1000 mg/day for 28 days. =46avorable safety profile at = all doses. Bioavailable in plasma at all doses. Modulated mitochondrial g= ene expression in muscle biopsies at 500 and 1000 mg.

Phase 2 in middle-aged adults (Singh et al., 2= 022, Cell Reports Medicine =E2= =80=94 the ATLAS trial). 88 sedentary middle-aged adults, = 4 months of supplementation, 500 mg or 1000 mg daily. Results: roughly 12= % improvement in leg muscle strength, clinically meaningful improvements = in VO2 peak and 6-minute walk test at 1000 mg, reduced plasma acylcarniti= nes (better mitochondrial fuel efficiency), reduced CRP (lower inflammati= on), and increased mitophagy and mitochondrial proteins in muscle biopsie= s.

2025 cardiovascular trial (iScience). UA improved cardiovascu= lar biomarkers in humans. Preclinical models showed reversal of systolic = and diastolic dysfunction in aging hearts and heart failure models.

2025 immune function trial (Nature Aging). 50 healthy adults,= 1000 mg/day for 4 weeks. Improved markers of immune fitness.

Dosing patterns from the literat= ure

500 mg/day shows benefit but consistently less than 10= 00 mg. 1000 mg/day is the dose used in most positive trials and appears t= o be the evidence-supported dose. Timing: morning, with or without food =E2= =80=94 absorption isn=E2=80=99t significantly affected by food. Time to e= ffect: gene expression changes appear within 4 weeks; functional improvem= ents typically reported at 2=E2=80=934 months.

Why I Think UA Is Underrated

Here=E2=80=99s my honest take after digging through th= is.

It targets mitophagy directly. = Almost no other oral compound does this reliably in humans. Mitophagy dec= line is one of the most fundamental drivers of aging.

It=E2=80=99s a postbiotic, not a synthetic dru= g. Your gut already makes it, sometimes. The body already = has machinery to handle it. The safety profile across trials reflects thi= s.

The mechanisms are convergent. = Mitochondrial quality, inflammation, senescence, neuroprotection, muscle = function, cardiovascular function, immune function =E2=80=94 these aren=E2= =80=99t separate problems. They=E2=80=99re all downstream of mitochondria= l decline. A compound that addresses the upstream cause has multi-system = effects.

The human data is real. This is= n=E2=80=99t a =E2=80=9Crodents only=E2=80=9D story. We have multiple plac= ebo-controlled human trials with measured outcomes in muscle biopsies, pl= asma biomarkers, and functional performance.

It pairs logically with other interventions. It doesn=E2=80=99t compete with peptides, exercise, or othe= r longevity tools. It addresses a different layer of the cellular machine= ry.

What I think holds it back from broader awareness: it=E2= =80=99s not flashy or new, no instant subjective effect like a stimulant = or peptide cycle. Effects are slow and structural, measured in weeks to m= onths. Marketing has been dominated by one premium-priced commercial bran= d, which has shaped the conversation. And it doesn=E2=80=99t fit cleanly = into the peptide narrative, so peptide-focused communities (mine included= ) sometimes overlook it.

A Note on Product Quality

One thing worth flagging if you=E2=80=99re resea= rching this further: the supplement market for UA is a mes= s.

A lot of products labeled =E2=80=9CUrolithin A=E2=80=9D= or =E2=80=9Cpomegranate complex=E2=80=9D actually contain ellagitannin o= r ellagic acid blends =E2=80=94 the precursors, not UA itself. Remember, = =7E60% of people can=E2=80=99t efficiently convert those precursors. So b= uying a =E2=80=9Cpomegranate extract=E2=80=9D hoping to get UA is essenti= ally gambling on your microbiome.

When you check labels, you want to see Urolithin A listed directly as the active ingredient, with a= specified milligram amount =E2=80=94 not a =E2=80=9Cproprietary blend=E2= =80=9D hiding the dose, and not just =E2=80=9Cellagitannins=E2=80=9D or =E2= =80=9Cellagic acid.=E2=80=9D

The honest reality: every single published human= clinical trial on UA has used Mitopure, ma= de by Amazentis and sold under the Timeline brand. It=E2=80=99s a patente= d form with greater than 98% purity. That=E2=80=99s not me selling it =E2= =80=94 that=E2=80=99s just what the literature shows. When researchers wa= nted to study UA in humans, this is the form they used. Generic UA produc= ts may be perfectly fine, but they don=E2=80=99t have direct clinical dat= a behind them at specified doses. Some are well-tested by third parties; = others aren=E2=80=99t.

If you want the version that matches the clinica= l trial literature exactly: Timeline Mitopure on Amazon

If you go with a generic UA product, look for:

  • Uroli= thin A listed as the active ingredient (not =E2=80=9Cpomegranate extract=E2= =80=9D or =E2=80=9Cellagitannin complex=E2=80=9D)

  • A spe= cified mg dose, 500 mg or 1000 mg per serving to match the trial doses

  • Third= -party testing or COA available

  • A rep= utable brand with transparent sourcing

Either way =E2=80=94 verify the label says Urolithin A, not a precursor complex.

Things Worth Researching =46urth= er

If you=E2=80=99re going down the rabbit hole, here=E2=80= =99s what=E2=80=99s worth understanding more deeply.

Mitophagy biology in general =E2=80=94 PINK1/Parkin, B= NIP3, NIX pathways. The hallmarks of aging (L=C3=B3pez-Ot=C3=ADn et al.) = and where mitochondrial dysfunction sits among them. Microbiome variabili= ty =E2=80=94 why some people convert ellagitannins to UA and others don=E2= =80=99t. Synergy with NAD+ precursors, exercise, and caloric restriction,= all of which affect mitochondrial pathways. The 2025 Palikaras lab paper= on calcium-dependent mitophagy and inter-organellar communication =E2=80= =94 the most mechanistically sophisticated UA paper I=E2=80=99ve seen. An= d the question of long-term effects: most trials are 4 weeks to 4 months.= Lifespan-style data in humans doesn=E2=80=99t exist yet.

=46inal Thoughts

UA is one of those compounds that doesn=E2=80=99t get = talked about enough because it doesn=E2=80=99t have a sexy story. There=E2= =80=99s no =E2=80=9Cyou=E2=80=99ll feel it on day one.=E2=80=9D There=E2=80= =99s no dramatic transformation photo. What there is, is a steadily growi= ng body of evidence that it does something genuinely fundamental at the c= ellular level =E2=80=94 restoring a process that nearly every other longe= vity intervention is trying to influence indirectly.

If aging is partly a story about damaged mitochondria = piling up faster than your cells can clear them, UA is one of the few too= ls that addresses that exact problem head-on.

Whether that translates into long-term human longevity= outcomes is a question the next decade of research will answer. But the = mechanisms, the human safety data, and the multi-system effects already m= ake it worth knowing about deeply =E2=80=94 even if you never personally = use it.

This is for research and educational purposes only= . Nothing in this piece is medical advice, and this isn=E2=80=99t a recom= mendation to use UA personally. If you=E2=80=99re interested in the topic= for any non-research reason, that=E2=80=99s a conversation for a qualifi= ed medical professional who knows your situation.

If this was useful, share it with someone who=E2=80=99= s been chasing the longevity rabbit hole and hasn=E2=80=99t come across U= A yet =E2=80=94 and let me know in the comments what underrated compound = you=E2=80=99d like me to break down next.

=E2=80=94 Derek

References

=46oundational mitophagy research

=

Ryu D, Mouchiroud L, Andreux PA, et al. <= em>Urolithin A induces mitophagy and prolongs lifespan in C. elegans and = increases muscle function in rodents. Nature Medicine. 2016;22= (8):879-888. doi:10.1038/nm.4132

Phase 1 human safety and bioavailability

Andreux PA, Blanco-Bose W, Ryu D, et al. = The mitophagy activator urolithin A is safe and induces a molecular s= ignature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1(6):595-603. =46ull text

Phase 2 muscle strength and exercise performan= ce trial (ATLAS)

Singh A, D=E2=80=99Amico D, Andreux PA, et al. Urolithin A improves muscle strength, exercise performance, and= biomarkers of mitochondrial health in a randomized trial in middle-aged = adults. Cell Reports Medicine. 2022;3(5):100633. =46ull text

2025 cardiovascular trial

Liu S, =46aitg J, Tissot C, et al. Ur= olithin A provides cardioprotection and mitochondrial quality enhancement= preclinically and improves human cardiovascular health biomarkers. = iScience. 2025;28(2):111814. =46ull text

2025 calcium-dependent mitophagy and inter-org= anellar mechanism

Roussos A, Kitopoulou K, Borbolis =46, et al. Urolithin A modulates inter-organellar communication via calcium= -dependent mitophagy to promote healthy ageing. Autophagy. 202= 5;21(12):3097-3122. =46ull text

Muscle aging mechanism review

=46aitg J, D=E2=80=99Amico D, Rinsch C, Singh A.= Mitophagy Activation by Urolithin A to Target Muscle Aging. Calcified Tissue International. 2024;114(1):53-59. =46ull text

Sports nutrition applications

Emerging evidence of Urolithin A in sports nutriti= on: bridging preclinical findings to athletic applications. =46= rontiers in Nutrition. 2025;12:1585922. =46ull text

Alzheimer=E2=80=99s disease (preclinical)

Jayatunga DPW, Hone E, Khaira H, et al. <= em>Therapeutic Potential of Mitophagy-Inducing Microflora Metabolite, Uro= lithin A for Alzheimer=E2=80=99s Disease. Nutrients. 2021;13(1= 1):3744. =46ull text

Urolithin A improves Alzheimer=E2=80=99s disease c= ognition and restores mitophagy and lysosomal functions. bioRx= iv. 2024. Preprint

Parkinson=E2=80=99s disease (preclinical)

Urolithin A in Health and Diseases: Prospects for = Parkinson=E2=80=99s Disease Management. Antioxidants. 2023;12(= 7):1479. =46ull text

Urolithin A improves Parkinson=E2=80=99s disease-a= ssociated cognitive impairment through modulation of neuroinflammation an= d neuroplasticity. Experimental Neurology. 2025. PubMed

Comprehensive CNS review

Urolithin A in Central Nervous System Disorders: T= herapeutic Applications and Challenges. Biomedicines. 2025;13(= 7):1553. =46ull text

Heart failure (H=46pE=46)

Urolithin A Restores Mitochondrial =46unction and = Reverses Cardiac Remodeling in Heart =46ailure with Preserved Ejection =46= raction. bioRxiv. 2025. Preprint

Independent supplement assessment

=

Alzheimer=E2=80=99s Drug Discovery =46oundation Cognitive Vitality= Report =E2=80=94 Urolithin A

Upgrade t= o paid

You're= currently a free subscriber to Research Radar. =46or the full experience, upgrade your subscription.

Upgrade to paid

&=23160;=
Share
&=23160;=
&=23160;=
3D=22=Like
3D=22=22=Comment
3D=22=22Restack
&=23160;=

=C2=A9 2026 Derek Pruski
548 Market Street PMB 72296, San =46rancisco, CA 94104
Unsubscribe

3D=22Start
3D=22=3D=22=22
--69f66573_3c00c9e0_cf0f--